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Introduction
Erythropoietin (EPO) is a pleiotropic cytokine primarily known as the key regulator of erythroid progenitor cell differentiation (Jacobson et al., 1957) . EPO is synthesized in the renal cortex in response to erythropoietic signaling, and the distribution of EPO thus produced is generally restricted to the vasculature (Eckardt and Kurtz, 2005) . EPO also exhibits broad cytoprotective and neuroprotective effects in vitro and in vivo. Biosynthesis of EPO mediating cytoprotection occurs locally in tissues, and EPO and EPO receptor (EPOR) expression increase following injury (Juul et al., 1998 , Grasso et al., 2005 . EPOR can be detected in neurons, astrocytes, and microglia in the central nervous system (CNS) and in multiple peripheral organs, including the heart, kidney, liver, lung, pancreas, and skeletal muscle (Liu et al., 1997 , Juul et al., 1998 , David et al., 2002 , Calvillo et al., 2003 , Assaraf et al., 2007 , Medana et al., 2009 , Joshi et al., 2014 .
The receptors mediating erythropoiesis and neuroprotection by EPO are distinct. A homodimeric receptor comprising two EPOR mediates erythropoiesis, while the cytoprotective effects of EPO are mediated by a heteromeric receptor composed of EPOR and the GM-CSF/IL-3/IL-5 receptor common beta-chain (CD131, CSF2RB) (Jubinsky et al., 1997 , Brines et al., 2004 , Leist et al., 2004 , Chateauvieux et al., 2003 , Puskovic et al., 2006 , Savino et al., 2006 , Mammis et al., 2009 , Ehrenreich et al., 2011 , Nachbauer et al., 2011 , Jang et al., 2014 . Achieving therapeutically meaningful levels of rhEPO in the CNS with an intact blood-brain-barrier (BBB) requires direct intracranial injection or high-dose systemic administration. High-dose rhEPO, however, is associated with a risk of side effects, including thrombotic events (Drüeke et al., 2006 , Singh et al., 2006 ; therefore, a selective EPOR/CD131 agonist may have a therapeutic advantage over rhEPO for CNS indications.
Selective activation of the EPOR/CD131 receptor was reported using recombinant EPO variants and EPO mimetic peptides. For example, carbamoylated EPO (CEPO), desialylated derivatives of EPO, and several EPO-derived peptides signal via the tissue-protective EPOR/CD131 without any measurable erythropoietic activity (Erbayraktar et al., 2003 , Brines et al., 2004 , Leist et al., 2004 (Wogulis et al., 2005) , and are referred to herein as human neuronal cells.
Generation of EPOR-and EPOR/CD131-overexpressing cell lines.
The human embryonic kidney cell line HEK-293 (ATCC-1573) was propagated in DMEM supplemented with FBS (10%).
HEK-293 cells over-expressing the EPOR alone were produced by transfection with a commercial mammalian expression vector containing the human EPOR gene and a puromycin selection marker (Gencopoeia, Rockville MD; EX-A0440-M68) using the FuGENE HD transfection reagent (Promega, Madison WI) followed by selection in 5 µg/ml puromycin. HEK-293 cells over-expressing CD131 alone were produced by transfection with a commercial mammalian expression vector containing the human CSF2RB gene and a hygromycin B selection marker (Gencopoeia EX-Z5874-M67) followed by selection in 150 µg/ml hygromycin B. HEK-293 cells over-expressing both the EPOR and CD131 were generated by transfecting the EPOR expression vector (EX-A0440-M68) into the HEK293/CD131 cell line followed by selection in puromycin and hygromycin B (5 µg/ml and 150 µg/ml, respectively).
M O L M a n u s c r i p t # 9 8 4 0 0 1 0 medium, B27 supplement, and Glutamax® (5 mM). The cells were plated at a density of 50,000 cells per well in 96-well multiwell plates and maintained in a humidified incubator at 37°C with 5% CO 2 .
Primary human renal epithelial cells. Normal human RPTEC (Lonza/Clonetics) were received at passage 2 and were seeded and grown according to the manufacturer's protocol. The RPTEC were maintained in basal medium (REBM; Lonza/Clonetics) supplemented with recombinant human epidermal growth factor, recombinant human insulin, hydrocortisone, epinephrine, transferrin, triiodothyronine, gentamycin, amphotericin B, and 0.5% FBS (Lonza/Clonetics).
Signaling assays. For assays employing HEK293 and derived cell lines, the cells were plated in 6-or 24-well plates 48 hour prior to the assay. For assays employing human neuronal cells, assays were performed 7 to 21 days after plating. One hour prior to the assay, the media were removed and replaced with fresh media. For the signaling assays measuring phosphorylation of AKT (HEK293 and derived cells lines only), cells were detached using DPBS without Ca 2+ or Mg 2+ , collected by centrifugation, suspended in DMEM supplemented with 0.1% FBS, plated in 6-well tissue-culture plates, and assayed between 30-45 minutes after plating. Compound stock solutions were prepared in DMSO at 1,000x final concentration, and final dilutions were prepared immediately before the assay in cell culture medium.
Compound, rhEPO, and control cultures contained identical final concentrations of DMSO (0.1% by volume). Cell plates and assay solutions were equilibrated to room temperature prior to the assay. The 
Results
Cytoprotective EPO receptor agonist compounds were identified from a small-molecule library of putative EPO receptor agonist tool compounds (Punnonen et al., Abstract #335AAN11D1; 63rd Annual
Meeting of the American Academy of Neurology, 2011). The design of the initial library was facilitated by the structure-activity relationship (SAR) information available from small molecule (Qureshi et al., 1999 , Goldberg et al., 2002 and allosteric peptide (Naranda et al., 1999 , Naranda et al., 2002 agonists of the EPO receptor, and allosteric small molecule agonists of the structurally related TPOR (EricksonMiller et al., 2005 , Desjardins et al., 2006 , Dziewanowska et al., 2007 , Kim et al., 2007 , Kalota and Gewirtz, 2010 , Abe et al., 2011 , as well as structural data on the receptors (Livnah et al., 1996 , Livnah et al., 1999 , Carr et al., 2001 ). An initial hit was identified based on receptor interaction and EPO-like functional activity, and subsequent compound designs for developing an SAR for in vitro neuroprotection Figure 1B , and its synthesis is described under Supplemental Data. STS-E412 has drug-like physical properties (MW = 318.8, cLogP = 3.3, topological polar surface area = 62 Å 2 ) and a water solubility of 0.0032 mg/ml (pH 7, PBS), which was determined by HPLC-UV analysis of the dissolved compound in a saturated solution after 90 minutes of shaking.
To evaluate EPOR activation in primary non-erythroid cells, we established cultures of primary human neuronal cells derived from human fetal cortical brain tissue. rhEPO produced a dose-dependent increase in the amount of phosphorylated EPOR in these primary human neuronal cell cultures ( Figure   This article has not been copyedited and formatted. The final version may differ from this version.
. Basal levels of the pEPOR averaged 0.33 ± 0.1 pg/µg protein (mean ± S.D., range: 0.23-0.91 pg/µg). The apparent EC 50 for rhEPO regarding EPOR phosphorylation was near 1 IU/ml ( Figure 1A) , and increasing the rhEPO concentration to greater than ~10 IU/ml did not provide an additional increase in EPOR phosphorylation. In the same primary cultures, STS-E412 also increased phosphorylation of the EPOR ( Figure 1B) . The maximal effect of STS-E412 was at least comparable to or higher than that induced by rhEPO ( Figure 1B) . The STS-E412-induced increase in EPOR phosphorylation was dosedependent and significant at concentrations as low as 60 nM. STS-E412 increased pEPOR levels approximately 4-fold over background in three independent cultures of primary human neuronal cells.
The increase in pEPOR in HCC produced by 10 IU/ml rhEPO (n=6) was not statistically different from that produced by 5 μM STS-E412 (n=8) based on student t-test (p=0.479).
To further examine signaling events induced by STS-E412, we generated HEK293 cell lines over-expressing the EPOR and CD131 (Figure 2 , A-D) or the EPOR alone ( Figure 2E ). In HEK293 cells
Both rhEPO and STS-E412 triggered phosphorylation of JAK2 ( Figure 2C ) and AKT ( Figure 2D) in HEK293 cells over-expressing the EPOR and CD131. In four independent experiments, STS-E412 increased pJAK2 by 1.52 ± 0.23 fold over basal levels with apparent EC 50 values of approximately 1-10 nM ( Figure 2C and data not shown). By comparison, 10 IU/ml rhEPO increased pJAK2 by 2.2 ± 0.2 fold over basal levels ( Figure 2C ). Increases in pJAK2 produced by 10 IU/ml rhEPO vs. that produced by 1-3.7 nM STS-E412 were statistically different by student t-test (p<0.035) while increases in pJAK2 produced by 10 IU/ml rhEPO vs. 11-100 nM STS-E412 were not significantly different (rhEPO vs. 11
nM STS-E412, p=0.072; rhEPO vs. 33 nM STS-E412, p=0.151; rhEPO vs. 100 nM STS-E412, p=0.109).
HEK293 cells and HEK293-derived cell lines contained relatively high basal levels of pAKT, and increases in pAKT above basal levels, with either rhEPO or STS-E412 treatment, were very small (data not shown). To circumvent this limitation, we found that transferring cells to media containing 0.1% FBS produced a transient decrease in the level of pAKT (to approximately 30-50% of basal levels) that was persistent for approximately 1 hour (data not shown). Under these conditions, STS-E412 also significantly increased the level of pAKT in HEK293 cells over-expressing the EPOR and CD131 ( Figure   2D ). In four independent experiments, STS-E412 increased pAKT levels by 1.82 ± 0.4 fold over basal levels with apparent EC 50 values of 1-10 nM ( Figure 2D and data not shown). In six independent experiments, 10 IU/ml rhEPO increased pAKT by 2.45 ± 0.91 fold over basal levels ( Figure 2D and data not shown). Increases in pAKT produced by 10 IU/ml rhEPO vs. those produced by STS-E412 were significant at all tested concentrations (p<5.6x10 Figure 2E ), while pEPOR levels in the presence of STS-E412 were indistinguishable from those in the controls. In EPOR-over-expressing HEK293 cells, rhEPO produced an increase in pEPOR in a dosedependent manner. In contrast, STS-E412 at concentrations ranging from 1 nM to 60 µM did not increase pEPOR levels in the HEK293 cells over-expressing the EPOR alone ( Figure 2E and data not shown).
Increases in pEPOR produced by 10 IU/ml rhEPO vs. those produced by STS-E412 (tested at concentrations from 2 μM -60 μM) were significant at all tested concentrations (p<0.00011).Consistent with our finding in HEK293 cells, STS-E412 did not produce increases in pEPOR in the erythroid cell line TF-1 over a similar concentration range, whereas 10 IU/ml rhEPO resulted in increases in pEPOR of approximately 2 fold (1.94 ± 0.16 fold, mean ± S.D., range: 1.83-2.12, n = 3; data not shown).
Proliferation assays with the erythroleukemia cell line TF-1 ( Figure 3A , 3B) and primary human bone marrow-derived CD34 + cells ( Figure 3C, 3D ) support the view that STS-E412 does not stimulate the erythropoietic EPOR/EPOR homodimer. RhEPO induced dose-dependent increases in both TF-1 and CD34 + cell numbers ( Figure 3A and Figure 3C , respectively). In contrast, STS-E412 at concentrations up to 1,000 nM had no effect on TF-1 or CD34 + cell proliferation ( Figure 3B and Figure 3D , respectively).
At concentrations above 1,000 nM, STS-E412 decreased the proliferation of TF-1 cells ( Figure 3B ), while the proliferation of CD34 + cells was increased ( Figure 3D ). Student t-tests comparing of TF-1 proliferation in the presence of 10 IU/ml rhEPO vs. STS-E412 (Figure 3 -B) indicated these differences were significant (p<8.03x10 -5 ). In contrast, student t-tests comparing CD34 + cell proliferation in the presence of 10 IU/ml rhEPO vs. 30 μM STS-E412 were not significant (p=0.11) while differences between 10 IU/ml rhEPO and STS-E412 at 3 μM and lower concentrations were significant (p<0.024).
STS-E412 protected primary human neuronal cells from a staurosporine challenge ( Figure 4A ), protected primary rat hippocampal neurons from an excitotoxic glutamate challenge ( Figure 4B ) and protected primary human RPTEC from a H 2 O 2 challenge ( Figure 5A , 5B). All the protection assays followed a paradigm consisting of a 24-hour treatment with the test articles followed by a 24-hour challenge, and rhEPO was included in the experiments for comparison.
In human neuronal cells ( Figure 4A ), the basal extracellular LDH was 19.3 ± 1.7% of the total LDH (mean ± S.D.). Staurosporine treatment alone (500 nM) increased the extracellular LDH to 36.8 ± 7.2% of the total LDH (mean ± S.D., 1.9-fold increase). Pre-treatment with rhEPO attenuated the staurosporine-dependent increase in the extracellular LDH by approximately 40% (to 29.9 ± 2.9% of the total LDH). STS-E412 also protected the human neuronal cells from a staurosporine insult in a dosedependent manner with an apparent EC 50 value in the 1-10 nM range ( Figure 4A ). STS-E412 attenuated the increase in extracellular LDH by approximately 50% at concentrations above 10 nM (e.g., to 27.3 ± 1.6% of the total LDH in the presence of 1,000 nM STS-E412). Based on student t-tests, difference in protection from staurosporine insult of human neuronal cells produced by 10 IU/ml rhEPO vs. those produced by STS-E412 at concentrations > 1 nM were not significant (rhEPO vs. STS-E412 at 1 nM, p=0.097; rhEPO vs. STS-E412 10 nM, p=0.697; rhEPO vs. STS-E412 at 100 nM, p=0.361; rhEPO vs.
STS-E412 at 1000 nM, p=0.547).
In primary rat hippocampal neuronal cultures, pre-treatment with rhEPO attenuated the glutamate-dependent increase in extracellular LDH by approximately 70%. Similarly, STS-E412 protected primary rat hippocampal neurons from glutamate challenge with a maximal protection at concentrations above 10 nM ( Figure 4B ). Concentrations of STS-E412 above 10 nM attenuated the increase in extracellular LDH by up to 46 ± 16%. Based on student t-tests, 10 IU/ml rhEPO produced significantly greater protection from glutamate insult in rat hippocampal neurons than STS-E412 (rhEPO vs. STS-E412 at 1 nM, p=0.0071; rhEPO vs. STS-E412 10 nM, p=0.0128; rhEPO vs. STS-E412 at 100 nM, p=0.0133).
In primary cultures of human RPTEC, pre-treatment with rhEPO attenuated the H 2 O 2 -dependent decrease in intracellular ATP in a dose-dependent manner with complete or near-complete protection in the 1-10 IU/ml concentration range (102 ± 0.75% of control at 10 IU/ml rhEPO; Figure 5A ). This protection was also reflected in a decrease in the level of extracellular LDH at similar rhEPO concentrations; rhEPO attenuated the increase in extracellular LDH by greater than 79% (97.5 ± 25% for M O L M a n u s c r i p t # 9 8 4 0 0 2 1 H 2 O 2 -dependent decrease in intracellular ATP in a dose-dependent manner with nearly complete protection at low nanomolar concentrations and complete protection at concentrations near 1 nM (103.3 ± 3.8% at 1 nM STS-E412; Figure 5A ). This protection was also reflected in a decrease in extracellular LDH at similar STS-E412 concentrations, and complete protection was observed at 0.1 nM STS-E412
(102 ± 13% compared with the unchallenged control; Figure 5B ). Based on student t-test, 10 IU/ml rhEPO did not produce significantly more protection form H 2 O 2 challenge than the optimal concentration of STS-E412 (LDH read-out: rhEPO vs. 0.1 nM STS-E412, p=0.303; Cell Titer Glo read-out: rhEPO vs.
1 nM STS-E412, p=0.933). Protection from H 2 O 2 challenge was reduced at the highest concentrations of rhEPO and STS-E412 ( Figure 5A , 5B).
A preliminary assessment of the suitability of STS-E412 for in vivo studies was performed using permeability and off-target activity assays. STS-E412 demonstrated high in vitro permeability in a PAMPA with a P e value of 15 × 10 -6 cm/s. The bidirectional transport of STS-E412 at 10 µM across a Table 1 ).
Caco-2 cell monolayer was determined via LC-MS/MS detection. STS-E412 demonstrated
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Discussion
EPO has emerged as a pleiotropic cytokine that is important not only in the regulation of erythroid cell differentiation and survival but also as a potent cytoprotective agent in multiple organs.
The characterization of the tissue-protective effects of EPO has led to the identification of two distinct receptors for EPO: an EPOR/EPOR homodimer that mediates erythropoiesis and an EPOR/CD131
heteromeric receptor that mediates tissue-protective effects. Here we describe the discovery and characterization of the nonpeptidyl compound STS-E412, which selectively activates the tissue-protective EPOR/CD131 receptor.
The first reports of nonpeptidyl small molecule EPO receptor agonists described compounds activating the EPOR/EPOR homodimer. These compounds demonstrated EPO-like activities on hematopoietic precursor cells in vitro, while the potencies were relatively low (EC 50 > 1 µM), and the compounds had molecular weights > 1,000 Da (Qureshi et al., 1999 , Goldberg et al., 2002 . A dimeric 20-amino-acid peptide lacking sequence homology with EPO also activated the EPOR/EPOR homodimer in preclinical and clinical studies , Besarab et al., 2012 . The crystal structure of the dimeric EPO mimetic peptide bound to the EPOR confirmed that the binding is orthosteric (Livnah et al., 1996) . While none of these mimetics are likely to be orally bioavailable, these studies demonstrated the feasibility of developing small molecules that compete with EPO to bind the EPOR/EPOR homodimer.
Given the similarities in the mechanisms of activation and structures of the receptors for TPO and EPO (Vigon et al., 1992 , Boulay et al., 2003 , the success in discovering and developing small molecule TPOR agonists further suggested the feasibility of discovering small molecule mimetics of EPO. All the small molecule TPOR agonists reported to date activate the receptor by binding to allosteric sites outside of the native ligand-binding site and proximal to residues near the plasma membrane (Desjardins et al., 2006 , Dziewanowska et al., 2007 , Kim et al., 2007 , Erickson-Miller et al., 2009 , Kalota and Gewirtz, 2010 , Abe et al., 2011 , suggesting that allosteric compounds may have more promise as therapeutic agents targeting the EPO receptor when compared to compounds binding at the orthosteric sites. The M O L M a n u s c r i p t # 9 8 4 0 0 2 4 allosteric TPOR agonists described to date are also smaller than the previously described orthosteric EPOR agonists, supporting the potential to design compounds that cross the BBB. Allosteric small peptide agonists of the EPO receptor have been described, while no tissue-protective effects were reported (Naranda et al., 1999 , Naranda et al., 2002 . Small molecule compounds selective for the tissueprotective EPOR/CD131 heterodimer have the potential to overcome the limitations of EPO regarding tissue availability and may improve safety by avoiding the hematopoietic side effects.
A fundamental mechanism of the EPO-induced protective effect is the inhibition of apoptosis via the JAK2/AKT pathway and subsequent transcriptional regulation of anti-apoptotic proteins, including
Bcl-xL and Bax (Digicaylioglu and Lipton, 2001 , Wen et al., 2002 , Um and Lodish, 2006 , Wu et al., 2007a . EPO also protects cells against oxidative damage in vitro and in vivo (Solaroglu et al., 2003 , Wu et al., 2007b . STS-E412 activates the tissue protective EPOR/CD131 receptor at nanomolar concentrations in primary human neuronal cells and cell lines stably expressing the EPOR and CD131.
The magnitude of CD131 phosphorylation in response to STS-E412 was comparable to that induced by rhEPO in EPOR/CD131 transfectants. STS-E412 also increased phosphorylation of EPOR in these transfectants, but the magnitude of the effect was substantially lower than that induced by rhEPO. STS- 2004) . Previous studies demonstrating comparable cytoprotective effects of CEPO and EPO in nonhematopoietic tissues, including the CNS and kidneys (Leist et al., 2004 , Imamura et al., 2007 , Wang et al., 2007 , also support the conclusion that the primary receptor for EPO on neurons and RPTEC is EPOR/CD131.
Proliferation assays in TF-1 and CD34 + progenitor cells provide a more complex view of interactions between STS-E412 and cell surface receptors. TF-1 cells express IL-3, IL-5 and GM-CSF receptors (heteromeric receptors composed of distinct alpha subunits and CD131), and these cytokines stimulate TF-1 cell proliferation. TF-1 cells also express thrombopoietin receptor (TPOR) and thrombopoietin stimulates TF-1 cell proliferation (Drexler and Quentmeier, 1996) . That STS-E412 does not stimulate proliferation in TF-1 cells suggests that STS-E412 does not effectively interact with these receptors at concentrations below 3-10 µM. The observed decrease in TF-1 proliferation at higher concentrations may suggest STS-E412-mediated sequestration of the CD131 subunit, which is required for growth of the IL-3-or GM-CSF-dependent TF-1 cells. In contrast to TF-1 cells, the increase in CD34 + progenitor cell proliferation at STS-E412 concentrations above 3-10 µM may suggest a low affinity interaction with the EPOR/EPOR homodimer or TPOR, although this was not detectable in the receptor phosphorylation assays. The increase in CD34 + cell proliferation also suggests that the decrease in TF-1 proliferation at high concentrations is not due to a non-specific cytotoxic effect of STS-E412. Regardless of the mechanism underlying these contrasting results with different cell types, these effects occurred at STS-E412 concentrations several orders-of-magnitude above those producing cytoprotective effects and EPOR/CD131 receptor activation.
STS-E412 exhibited a bell-shaped dose-response curve in the EPOR/CD131 transfectants and RPTEC cells, but not in primary neuronal cells. These observations are not surprising in light of previous studies on the small molecule TPOR agonist eltrombopag, which resulted in bell-shaped dose-response curves in receptor-expressing cell lines (Xie et al., 2012) . In addition, eltrombopag triggered TPO-like STAT5 activation in CD34 + CD41 -progenitor cells, but in contrast to rhTPO, eltrombopag did not activate STAT3 or AKT in CD34 + CD41 + cells (Sun et al., 2012) . Bell-shaped dose-response curves were also
observed in previous in vitro studies on nonpeptidyl compounds activating the receptors for G-CSF and EPO (Tian et al., 1998 , Qureshi et al., 1999 . The formation of 1:1 receptor/ligand complex at high ligand concentrations was also shown to inhibit the activation of receptors for growth hormone and EPO (Fuh et al., 1992 , Schneider et al., 1997 . The crystal structure of the GM-CSF receptor in complex with CD131 revealed a 2:2:2 hexamer consisting of two GM-CSFR alpha chains, two CD131 chains, and two GM-CSF molecules, and also demonstrated the existence of a functional higher-order dodecamer, a hexamer dimer (Hansen et al., 2008) . The higher-order structures of the EPOR/CD131 complex are not known, while the GM-CSFRα/CD131 data suggest that similar higher-order structures form when CD131
associates with the EPOR. The bell-shaped dose-response curve triggered by STS-E412 suggests that, similar to the EPOR/EPOR, growth hormone, G-CSF and GM-CSF receptors, the formation of 1:1 receptor/ligand complex at high STS-E412 concentrations prevents the optimal activation of the EPOR/CD131 receptor. However, the exact mechanism of receptor activation by STS-E412 remains to be elucidated.
In the primary neuronal and kidney cell cytoprotection assays, STS-E412 exhibited significant cytoprotective effects following a range of cytotoxic challenges. These data are consistent with previous reports demonstrating broad cytoprotective effects of rhEPO, EPO variants selective for EPOR/CD131, and mimetic peptides (Konishi et al., 1993 , Sakanaka et al., 1998 , Erbayraktar et al., 2003 , Brines et al., 2004 , Leist et al., 2004 , Coleman et al., 2006 , Brines et al., 2008 , Ahmet et al., 2011 , Chen et al., 2012 .
The maximal protective effects in response to STS-E412 were comparable to those induced by rhEPO, and optimal responses were observed at low nanomolar concentrations in both neurons and RPTEC. It is worth noting that staurosporine inhibits many intracellular kinases and may inhibit activation of the tissue-protective EPOR/CD131 receptor and signaling molecules involved in protection. While our experimental paradigm used a 24 hours pre-treatment (in the absence of staurosporine) and staurosporine concentrations used in our experiments were relatively low, we cannot exclude the possibility that kinase inhibition affected the observed cytoprotective effects of rhEPO and STS-E412. This concern, however, for 24 hours prior to a staurosporine insult (500 nM). After culturing the cells for an additional 24 hours, the supernatants were harvested, and the LDH levels were measured as described in the Methods section.
The data represent the means + S.E.M. of six (rhEPO, STS-E412) or nine (control, staurosporine alone)
replicates. B: primary rat hippocampal cells were pre-treated with STS-E412 at the indicated concentrations or rhEPO (10 IU/ml) for 24 hours prior to a glutamate insult (100 μM). The cells were then cultured for an additional 24 hours. The supernatants were harvested, and the LDH levels were measured as above. An asterisk (*) represents a p-value < 0.05 compared to the control according to Student's t-test. 
